Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Treatment practices and outcomes of advanced stage classical Hodgkin lymphoma in India: An analysis from the hematology cancer consortium

View Full Paper
Ask AI
Bookmark
Share

Authors

DBDinesh BhuraniSDSanthosh Kumar DevadasSVSreeraj Vasudevan

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows 2-year event-free survival of 79% in advanced classical Hodgkin lymphoma, suggesting iPET response and IPS score are vital for prognosis.

Key Points

  • Complete response was achieved in 481 patients (68.4%) among those treated for advanced stage classical Hodgkin lymphoma.
  • The predominant chemotherapy protocol was ABVD, utilized in 628 patients (89%).
  • Assessment utilized FDG-PET/CT for interim response in 471 patients, leading to significant EFS metrics.
  • Combining iPET response and IPS score is suggested for improved patient risk stratification in advanced classical Hodgkin lymphoma.

Cite This Study

Bhurani et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d71dhttps://doi.org/10.1182/blood-2025-7133
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real world outcome of nodal T cell non-Hodgkin lymphoma from hematology cancer consortium registry in India2025
  2. 2Predictors of discordant end-of-treatment PET positivity in advanced-stage classical Hodgkin lymphoma patients with negative interim PET response2025
  3. 3Early-stage nodular lymphocyte predominant Hodgkin lymphoma: Disease characteristics, treatment pattern, and long-term outcomes from a tertiary care cancer institute in India2025
  4. 4Frontline ABVD Remains an Effective Option in Advanced-Stage Classical Hodgkin Lymphoma: Real-World Data from Turkey2026
  5. 5Treatment options, responses and outcome of 1220 classic Hodgkin lymphoma patients included in realysa, a prospective multicentric lysa cohort2025